These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26582402)

  • 1. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Bieber BA; Pisoni RL; Li Y; Morgenstern H; Akizawa T; Jacobson SH; Locatelli F; Port FK; Robinson BM
    J Am Soc Nephrol; 2016 Jul; 27(7):2205-15. PubMed ID: 26582402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
    Fuller DS; Robinson BM; Locatelli F; Pisoni RL
    Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Pisoni RL; Bragg-Gresham JL; Young EW; Akizawa T; Asano Y; Locatelli F; Bommer J; Cruz JM; Kerr PG; Mendelssohn DC; Held PJ; Port FK
    Am J Kidney Dis; 2004 Jul; 44(1):94-111. PubMed ID: 15211443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in anemia management practices in patients receiving hemodialysis and peritoneal dialysis: a retrospective cohort analysis.
    Wetmore JB; Peng Y; Monda KL; Kats AM; Kim DH; Bradbury BD; Collins AJ; Gilbertson DT
    Am J Nephrol; 2015; 41(4-5):354-61. PubMed ID: 26107376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.
    Karaboyas A; Zee J; Morgenstern H; Nolen JG; Hakim R; Kalantar-Zadeh K; Zager P; Pisoni RL; Port FK; Robinson BM
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1814-21. PubMed ID: 26286925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal anemia treatment with ESA in hemodialysis patients in relation to early versus late referral in everyday clinical practice in Central and Eastern European countries: baseline data.
    Malyszko J; Drozdz M; Zolkiewicz A; Rutkowski B
    Kidney Blood Press Res; 2012; 35(1):58-67. PubMed ID: 21876362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton Pump Inhibitors and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients: Results from the Japan Dialysis Outcomes and Practice Patterns Study.
    Nakashima A; Miyawaki Y; Komaba H; Kurita N; Onishi Y; Yokoo T; Fukagawa M
    Am J Nephrol; 2024; 55(2):165-174. PubMed ID: 37935135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
    Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
    JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan.
    Wish JB
    Kidney Int; 2011 Feb; 79(3):265-7. PubMed ID: 21228798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
    Luo J; Jensen DE; Maroni BJ; Brunelli SM
    Am J Kidney Dis; 2016 Nov; 68(5):763-771. PubMed ID: 27528373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients.
    McFarlane PA; Pisoni RL; Eichleay MA; Wald R; Port FK; Mendelssohn D
    Kidney Int; 2010 Jul; 78(2):215-23. PubMed ID: 20428102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform.
    Chertow GM; Liu J; Monda KL; Gilbertson DT; Brookhart MA; Beaubrun AC; Winkelmayer WC; Pollock A; Herzog CA; Ashfaq A; Sturmer T; Rothman KJ; Bradbury BD; Collins AJ
    J Am Soc Nephrol; 2016 Oct; 27(10):3129-3138. PubMed ID: 26917691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.
    Hasegawa T; Zhao J; Fuller DS; Bieber B; Zee J; Morgenstern H; Hanafusa N; Nangaku M
    Am J Nephrol; 2017; 46(1):11-17. PubMed ID: 28564644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemoglobin levels triggering erythropoiesis-stimulating agent therapy in patients with cancer: the shift after United States Food and Drug Administration policy changes.
    Stroupe KT; Tarlov E; Lee TA; Weichle TW; Zhang QL; Michaelis LC; Ozer H; Durazo-Arvizu R; Browning MM; Hynes DM
    Pharmacotherapy; 2012 Nov; 32(11):988-97. PubMed ID: 23108695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Hemoglobin Cycling and Its Clinical Impact on Outcomes in Thai End-Stage Renal Disease Patients Treated with Hemodialysis and Erythropoiesis-Stimulating Agent.
    Thanakitcharu P; Jirajan B
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S28-37. PubMed ID: 27266213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
    Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
    Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin.
    Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T
    Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perihospitalization patterns of hemoglobin levels and erythropoiesis-stimulating agent doses in US hemodialysis patients, 1998-2009.
    Foley RN; Solid CA; Lamb K
    Hemodial Int; 2014 Jan; 18(1):24-31. PubMed ID: 24131588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.